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AbstrAct
Adaptive optics (AO) ophthalmoscopy allows for non-
invasive retinal phenotyping on a microscopic scale, 
thereby helping to improve our understanding of retinal 
diseases. An increasing number of natural history studies 
and ongoing/planned interventional clinical trials exploit 
AO ophthalmoscopy both for participant selection, 
stratification and monitoring treatment safety and 
efficacy. In this review, we briefly discuss the evolution 
of AO ophthalmoscopy, recent developments and its 
application to a broad range of inherited retinal diseases, 
including Stargardt disease, retinitis pigmentosa and 
achromatopsia. Finally, we describe the impact of this 
in vivo microscopic imaging on our understanding of 
disease pathogenesis, clinical trial design and outcome 
metrics, while recognising the limitation of the small 
cohorts reported to date.
IntroductIon
Inherited retinal disease (IRD) is the leading cause 
of legal blindness in England and Wales among 
the working age population and the second most 
common in childhood.1 IRD is a group of clini-
cally heterogeneous conditions, which can result in 
diagnostic challenges, often thereby necessitating 
detailed multimodal retinal imaging, as well as 
electrophysiological and psychophysical evalua-
tion. They are subject to a broad range of research 
avenues and interventions which have been recently 
reviewed.2 Here, we categorise IRDs on the basis of 
natural history (stationary or progressive) and the 
primarily affected retinal cell type.
In vivo retinal imaging has been rapidly evolving 
over the last decades primarily due to advances in 
optics, electronics and computer technology. The 
introduction of optical coherence tomography 
(OCT) has revolutionised the clinical investigation 
of retinal diseases.3 4 One of the main limiting factors 
for in vivo retinal imaging is ocular aberrations, due 
to the optical imperfections of the eye.5 Adaptive 
optics (AO) can be employed in ophthalmology to 
overcome the aforementioned limitation.6
brIef overvIew of Ao retInAl ImAgIng
The incorporation of AO to any ophthalmo-
scopic technique, including fundus photography, 
OCT and scanning laser ophthalmoscopy (SLO), 
provides in vivo microscopic imaging.6–9 AO 
ophthalmoscopes typically use a wavefront sensor 
to measure the ocular monochromatic aberra-
tions and a deformable mirror to correct for 
the detected aberrations.6 9 10 Herein we will be 
focusing on AOSLO photoreceptor imaging as this 
is the modality that has been most extensively used 
in patients with IRD. By focusing a scanning light 
source on the photoreceptor layer and rejecting 
out-of-focus light through the use of a confocal 
aperture, axial sectioning is achieved, thereby 
increasing image contrast.8 11 Photoreceptors with 
relatively intact outer segments waveguide some 
incident light, and backscatter a very small frac-
tion (less than 0.1%), which is used for imaging.12 
When collecting that light in a confocal detector, 
the cone8 13 14 and perifoveal rod8 15 16 mosaics can 
be resolved. Several systems have been developed 
including both custom-built and commercially 
available devices.
The non-confocal backscattered light can also 
be exploited to reveal the photoreceptor inner 
segment mosaic. For example, the split detection 
(SD) technique (SD-AOSLO) does so by subtracting 
images created by capturing the light to the left of 
the confocal aperture with one detector and the 
light to the right of it with a different one.17 This 
recent development was transformational because 
cones with compromised outer segments (as would 
be anticipated in the majority of IRDs) can now be 
reliably identified for the first time. This has major 
implications for patient stratification and targeting 
of intervention.18–25
Due to light safety restrictions, each individual 
AOSLO raw frame is captured using very low illu-
mination power (~100 µW at the pupil) and thus 
the resulting images are inherently noisy. There-
fore, AOSLO image sequences are captured at each 
retinal location of interest, and used to create a 
higher signal-to-noise ratio (SNR) image by aver-
aging a few of these frames after correcting for 
eye motion and scanning distortions.26 These high 
SNR images are then stitched together to create 
a larger montage (figure 1). A range of photore-
ceptor metrics have been employed to date, with 
cone density for a given eccentricity being the most 
widely used, and usually compared with normative 
data from histology27 or imaging studies.13 28 29 
Other metrics include (1) cone spacing—average 
distance between cells in a given location, (2) 
Voronoi analysis (figure 1) which involves counting 
the number of neighbouring cells based on the 
distance between them, thereby assessing mosaic 
geometry,28 (3) reflectivity,18 and (4) metrics for 
the preferred orientation of cones and local spatial 
anisotropy.30
The combination of OCT and AO (AO-OCT) 
is an evolving field, aiming for 3D reconstruction 
and offers greater axial resolution compared with 
AOSLO.31
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Irds And Ao retInAl ophthAlmoscopy
The selected conditions below have been prioritised based on the 
ability of published AO ophthalmoscopy studies to demonstrate 
clinical, research or trial utility. There are inherent limitations 
due to the often small cohorts reported to date. These are usually 
small due to the vast genetic and phenotypic heterogeneity of 
IRDs, the low prevalence of each genotype and due to the diffi-
culty of establishing multicentre studies given the limited avail-
ability of AOSLO. However, similar limitations are often faced 
by other studies using other modes of high-resolution imaging. 
For clarity, we have included the number of subjects in each 
study we describe and whether the patients were molecularly 
confirmed (online supplementary table 1).
macular dystrophies
Stargardt disease
Stargardt disease (STGD1) is the most common form of hered-
itary macular dystrophy.32 Confocal AOSLO (cAOSLO) has 
demonstrated abnormal and decreased cone spacing in regions 
corresponding to areas of reduced and irregular fundus auto-
fluorescence (FAF), in predominantly late-onset/foveal sparing 
molecularly proven patients (11 of 12 patients).33 Moreover, 
foveal retinal pigment epithelium (RPE) cells were imaged in 
areas where the photoreceptor mosaic appeared disrupted in 
confocal reflectance imaging, suggesting photoreceptor loss 
preceding RPE cell loss—although the application of SD-AOSLO 
would address whether there are in fact cone inner segments 
present.33 Song et al also reported increased photoreceptor 
spacing, in genetically proven STGD1 (n=2), in otherwise 
normal appearing areas on OCT and FAF imaging; also consis-
tent with photoreceptor loss preceding clinically detectable RPE 
disease.34 Interestingly, SD-AOSLO derived cone density has 
been shown to correlate well with OCT measurements of outer 
nuclear layer thickness and retinal sensitivity (n=14; all molec-
ularly confirmed), demonstrating a valuable structure-function 
association, even though the extent of atrophic changes was not 
corresponding to visual aquity.19 Using cAOSLO and SD-AOSLO, 
Tanna et al investigated the reliability and repeatability of cone 
counting in patients with STGD1 (n=12), suggesting superior 
reliability and repeatability with SD-AOSLO.35
Longitudinal imaging studies of the photoreceptor and RPE 
mosaic in large molecularly proven specific STGD1 cohorts 
(ie, childhood-onset, adult-onset and late-onset/foveal sparing) 
are needed to evaluate cellular disease progression and poten-
tially identify the most suitable participants for ongoing and 
multiple planned gene therapy and pharmacological interven-
tions.19 33 34 36 AO ophthalmoscopy may be a useful method of 
monitoring in trials, since ‘classic’ parameters of ophthalmolog-
ical examination including best corrected visual acuity (BCVA) 
are not sufficiently sensitive outcome measures for conditions 
such as STGD1.37
Best disease
Normal photoreceptor structure and cone densities in areas 
adjacent to clinically visible lesions have been reported, with 
persistent photoreceptor structure overlying stage 1 and 2 vitel-
liform Best disease lesions, in keeping with relatively intact 
visual acuity (VA).38 Using cAOSLO and SD-AOSLO, variable 
photoreceptor architecture has been observed to be associated 
with different stages of the disease and the location within the 
lesions, including reduced cone density, due to major discontinu-
ities/gaps in the mosaic, and cone inner segment enlargement.23
X-linked retinoschisis
Duncan et al39 have reported increased and irregular cone 
spacing within the foveal schisis characterising X-linked reti-
noschisis. Interestingly, cone spacing was normal and regular 
elsewhere. The preserved waveguiding cones at the fovea and 
eccentric macular regions may indicate increased likelihood of 




This group of disorders has been reviewed in detail previously40 
(figure 2).
Achromatopsia
Early investigations with cAOSLO identified ‘dark spaces’ 
in the cone mosaic, increased cone spacing and/or decreased 
cone density in patients with achromatopsia (ACHM) 16 18 41 42 
(figure 2: 1C and 2C). Marked variability in the cone mosaic 
has been observed across patients; with no significant differ-
ence between the two most common genotypes, CNGA3 and 
CNGB342 43 ; and the rarer GNAT2 genotype associated with 
figure 1 Adaptive optics scanning laser ophthalmoscopy (AOSLO) imaging of a healthy subject and cone quantification. (A) Colour fundus 
photograph (30°) of a healthy subject (MM_0136), with AOSLO montage superimposed. The white square encompasses the foveal avascular zone 
(region of interest, ROI), which is magnified in (B). (B) Confocal AOSLO of the ROI, the estimated foveal centre is marked with a white cross and 
the 55 μm×55 μm area of sampling for cone counting with a white box at 0.35° from the foveal centre. Scale bar=100 μm. (C) Magnified view of 
the sampled area. (D) The sampled area with cones marked. (E) The sampled area with Voronoi domains. (F) The Voronoi representation coloured 
according to the number of neighbouring cells. Green represents six-sided bound cones. Scale bar for (C–F)=20 μm.
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the relatively least disrupted photoreceptor mosaic.18 44 Until 
the advent of SD-AOSLO, it was unknown if these ‘dark spaces’ 
harboured non-waveguiding cones or indicated loss of cones—
with the presence or absence of cones being directly related 
to potential rescue with intervention. Simultaneous cAOSLO 
and SD-AOSLO have allowed the identification of cone inner 
segment structure in these spaces,17 24 25 45 with transformational 
implications on our understanding of ACHM and participant 
selection for ongoing CNGA3-ACHM and CNGB3-ACHM 
gene therapy trials (figure 2: 1D and 2D). Given the potential 
disconnect between OCT and AO measures of cone integrity 
and the ability of AO to directly visualise the target cones for 
gene replacement, non-confocal SD-AOSLO imaging would be 
the modality of choice to identify patients most likely to benefit 
from cone-directed rescue.
In the largest AO ophthalmoscopy ACHM study to date 
(n=52), significantly decreased peak foveal cone densities and 
increased spacing, using SD-AOSLO in CNGB3-ACHM has 
been reported.45 Interestingly, the peak foveal density ranges 
were shown to overlap between the previously described OCT 
grades,43 in keeping with the aforementioned disconnect.
Reduced reflectivity in the majority of residual cones in 
CNGA3 and CNGB3 has also been noted, with relative preser-
vation in GNAT2. Changes in cone reflectivity could potentially 
provide a clinical trial outcome metric.18 42
Directly relevant to the ongoing debate on whether ACHM is 
significantly progressive,40 based on serial OCT and AOSLO, a 
longitudinal study of CNGB3-ACHM, with follow-up of 6–26 
months, showed little or no detectable change in foveal cone 
structure over time.24
Blue cone monochromacy
Blue cone monochromacy (BCM) is associated with a range 
of opsin array genotypes, affecting both L and M cones.40 The 
condition is X-linked, and despite female carriers being asymp-
tomatic, cAOSLO has demonstrated variably reduced cone 
density, increased spacing and disrupted organisation, with 
phenotypic variability likely relating to random X-chromosome 
inactivation.46 Affected men have a more severe phenotype, 
although the degree of cone mosaic disruption is also highly vari-
able and may be partly related to specific genotype group.47 The 
figure 2 Adaptive optics scanning laser ophthalmoscopy (AOSLO) imaging of the cone dysfunction syndromes. Column (A) shows the infrared 
reflectance (IR) fundus photographs for each subject (1, 2, 3, 4). The green arrow represents the section in which the optical coherence tomography 
(OCT) (Spectralis HRA+OCT, Heidelberg Engineering, Heidelberg, Germany) presented in column (B) is taken; the black square represents the 450 
μm×300 μm region of interest imaged with AOSLO which is presented in columns (C) and (D). Column (B) shows OCT horizontal scans through the 
fovea and the white arrows mark the corresponding AOSLO area (450 μm wide). Column (c) depicts confocal AOSLO (cAOSLO) and column (D) split 
detection (SD) AOSLO. Subjects (1) and (2) have achromatopsia associated with CNGB3 and CNGA3 gene mutations, respectively. (1C/2C) Dark 
spaces are observed, due to loss of cone waveguiding properties, which correspond to visible foveal cone inner segments in (1D/2D), respectively, 
with a substantial difference in cone numerosity between the two subjects. (3) A molecularly confirmed subject with blue cone monochromacy. 
(3C) Dark foveal centre, with a sparse array of large bright spots, which are believed to be S cones, immediately surrounding it. (3D) Remnant inner 
segment structure. (4) A molecularly confirmed subject with Bornholm eye disease (LIAVA haplotype). (4C) All cones are resolved in cAOSLO, with 
a few apparent non-waveguiding cones (dark spaces). (4D) SD-AOSLO does not resolve foveal inner segments due to the better preserved mosaic 
(smaller cone diameters and tighter packing geometry) compared with the other cone dysfunction syndromes. All AOSLO images were acquired using 
a custom-built AOSLO housed at University College London/Moorfields Eye Hospital, London. Scale bar=50 μm.
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L/M interchange haplotypes have been associated with signifi-
cantly greater residual parafoveal cone structure, with localised 
loss of waveguiding cones at the fovea. In contrast, the inac-
tivating Cys203Arg missense mutation genotype group is asso-
ciated with greater loss of waveguiding L/M cones. cAOSLO 
images of the cone mosaic typically show a dark foveal centre, 
with a sparse array of large bright spots, which are believed to 
be S cones, immediately surrounding it (figure 2C).47 48 It is 
possible to estimate with reasonable confidence the number of 
L and M cones in the parafovea, as they appear as dark gaps 
within the rod mosaic.46 cAOSLO has demonstrated a reduced 
number of cones in the parafovea (both reflective S cones and 
non-reflective L cones and M cones) to that of about 25% of 
normal, with evidence of even greater loss of cone cells in the 
locus control region deletion genotype group of BCM. More-
over, SD-AOSLO images have revealed remnant inner segment 
structure (figure 2B) both at the fovea and the parafovea.48 
Importantly, however, despite low cone density in BCM, the 
number is higher than that expected for the S cone submosaic, in 
keeping with remnant L/M cones.27 49 50
Overall, these AOSLO imaging studies have identified signif-
icant intersubject variability in cone mosaic integrity and illus-
trate the importance of cellular imaging in the identification of 
remnant cones that have the potential to be rescued in planned 
interventions.
Oligocone trichromacy and RGS9/R9AP-associated retinopathy 
(‘Bradyopsia’)
The cone photoreceptor mosaic in three patients with typical 
oligocone trichromacy has been investigated, and in keeping 
with the original disease mechanism hypothesis, a decreased 
number (‘oligocone’) of otherwise normal appearing foveal cones 
(thereby permitting ‘trichromacy’) were observed, with absence 
of visible structure beyond the central fovea.51 RGS9/R9AP-as-
sociated retinopathy is clinically indistinguishable from oligo-
cone trichromacy, but can be discerned using non-standard 
extended electrophysiological assessment or molecular genetic 
testing. However, unlike in oligocone trichromacy, cAOSLO has 
revealed a normal cone photoreceptor mosaic in subjects with 
RGS9/R9AP retinopathy,51 52 which is in agreement with the 
electroretinography (ERG) findings of normal initial response 
in dark-adapted flicker ERGs performed with a dim stimulus.53 
Cellular phenotyping is therefore able to readily differentiate 
between these two conditions with common clinical features—
with an intact photoreceptor mosaic in bradyopsia and disrup-
tion in oligocone trichromacy.
Bornholm eye disease
Similar to BCM, Bornholm eye disease (BED) is an X-linked 
cone dysfunction syndrome that is associated with mutations in 
the L/M gene array.54–58 Predominantly due to the heterogeneity 
in the underlying genotype (predominantly L/M interchange 
haplotypes), the degree of photoreceptor mosaic disruption in 
affected men is highly variable, with cone density ranging from 
near normal to more than 75% reduction59 (figure 2: 4C and 
4D). However, there is also high variability in the appearance 
of the cone mosaic within brothers who share the same geno-
type, likely owing to variations in L:M cone ratio.59 60 Cone 
density has been found to correlate with both axial length and 
the degree of myopia60; however, systematic analysis of the 
relationship between these factors and the specific underlying 
L/M opsin variant is lacking, due to small numbers of subjects 
within each genotype group to date. Additionally, previous 
investigations employing AOSLO imaging have been cross-sec-
tional, so there is a need for longitudinal studies to track larger 
genetically confirmed cohorts, both for BED and BCM, to deter-
mine natural history and thereby better establish the potential 
for intervention.
Rod dysfunction syndromes
Congenital stationary night blindness
Godara et al reported retinal structure in three patients with 
GRM6-associated congenital stationary night blindness.61 They 
identified a contiguous cone mosaic and normal cone densities 
with cAOSLO, in keeping with previous histopathology. They 
identified photoreceptor mosaic integrity and reported thinning 
of inner retinal layers on OCT, suggesting a functional defect 
in retinal neurotransmission, rather than a structural photore-
ceptor defect.61
Oguchi disease
Oguchi disease is a very rare form of night blindness having 
the unusual distinguishing features of the Mizuo-Nakamura 
phenomenon: diffuse fundus discoloration and return to normal 
colour after prolonged dark adaption.62 To probe the underlying 
basis of this intriguing phenomenon, the photoreceptor mosaic 
has been investigated, both in light and dark-adapted conditions, 
in two molecularly confirmed siblings.61 Normal photoreceptor 
densities were identified; however, rod reflectivity (unlike cone) 
was shown to increase over time, changing from scotopic to 
photopic conditions, suggesting that rods are responsible for the 
unique fundus findings in Oguchi disease.63
Fundus albipunctatus
Using fluorescence AOSLO and cAOSLO, Song et al have 
reported decreased foveal cone density and increased cone 
spacing at 10° of eccentricity, despite this predominantly being 
a rod disorder.64 No photoreceptors or RPE cells were visual-
ised within the albipunctate spots. Another study also identified 
decreased perifoveal cone density and mosaic disruption using 




In X-linked RPGR-associated retinopathy, there is a pheno-
typic heterogeneity (both intrafamilial and interfamilial) among 
affected men.66 Female carriers’ phenotypes can vary widely, 
ranging from asymptomatic to severely affected (although not 
to the extent of affected men) and almost always present with 
a radial pattern of increased retinal reflectivity, the so-called 
tapetal-like reflex.67 The patchy appearance of rods and cones 
observed both ex vivo and in vivo (mosaicism) is believed to be 
due to random X-chromosome inactivation.
Several studies have reported a decrease in cone density and/
or increased cone spacing using cAOSLO in patients with reti-
nitis pigmentosa (RP), with approximately half of the subjects 
having an established genetic diagnosis68–73 (figure 3). Sun et al21 
examined both patients with RP and Usher syndrome (USH) (see 
below) using cAOSLO and SD-AOSLO, and found that foveal 
cone density was reduced by up to 38% before VA was affected, 
without any visible findings on OCT (however, increased cone 
spacing was not identified in isolated RP cases). This was in 
keeping with a previous study reporting normal VA and retinal 
sensitivity in patients with up to 62% reduction in peak cone 
density.73 These studies illustrate the remarkable redundancy in 
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cone populations, the importance of multimodal imaging and the 
disconnect between retinal structure and function, with major 
implications for gene therapy, and also stem cell replacement 
strategies—including the potential need to successfully integrate 
smaller numbers of cones than previously believed.
A phase II/III trial has been undertaken with intravitreal 
implants of encapsulated human RPE cells engineered to contin-
uously secrete ciliary neurotrophic factor (CNTF) protein in 
patients with early-stage and late-stage RP.74 Patients were 
randomly assigned to receive a high-dose or low-dose implant in 
one eye and sham surgery in the fellow eye. Primary endpoints 
were change in BCVA at 12 months for late-stage RP and change 
in visual field sensitivity at 12 months for early RP. Neither 
study showed a therapeutic benefit. However, a pilot study using 
AOSLO in three patients with CNTF implants over a 24-month 
period found that cone density remained stable in eyes with 
a CNTF implant, whereas there was continued cone loss in 
untreated fellow eyes, suggesting that more sensitive metrics 
are needed as primary outcome measures in progressive diseases 
such as RP.71
Usher syndrome
AOSLO has been previously undertaken in one patient with USH 
type II, and three patients with USH type III.71 75 In USH-III, a 
relative preservation of foveal cone density was observed, with 
loss of cone structure in areas of absent retinal sensitivity.75 Using 
cAOSLO and SD-AOSLO as complementary modalities, Sun 
et al21 identified lower foveal and parafoveal cone densities in 
USH-II (n=4, USH2A) compared with non-syndromic RP (n=9 
(2 X-linked RP RPGR; 3 autosomal recessive RP=2 USH2A and 
1 EYS; 4 autosomal dominant RP=3 RHO and 1 RP1)) despite 
the normal appearance of interdigitation (IZ) and ellipsoid 
zones (EZ) on OCT, which was attributed by the authors to the 
decreased number of normal waveguiding cones (outer segment 
defects), possibly a result of the different molecular pathways 
affected in each condition and the localisation of the affected 
protein either in the connecting cilium or outer segment.21
figure 3 Multimodal imaging of retinitis pigmentosa. (A) Infrared reflectance (IR) fundus photograph of a subject (MM_0205) with X-linked 
retinitis pigmentosa associated with RPGR gene. The white arrow represents the section of the optical coherence tomography (OCT) presented in 
(B). (B) Horizontal transfoveal OCT line scan, with the white arrows indicating the width of the corresponding AOSLO imaged area in (D). (C) Fundus 
autofluorescence imaging, with the confocal AOSLO (cAOSLO) imaged area (D) superimposed over the foveal avascular zone and the white arrow 
represents the section presented in the OCT scan (B). (D) cAOSLO imaging revealing a disrupted waveguiding mosaic, not as uniform in appearance 
as in a healthy subject (figure 1). (E) Magnification of cAOSLO over the estimated foveal centre (marked with a white dashed square in (D)) shows 
irregularly waveguiding cones, which appear dim (some are indicated with white arrows); and (F) the corresponding split detection AOSLO in exact 
spatial registration showing relatively healthy-appearing cone inner segments, the white arrows indicate the corresponding inner segments for the 
irregularly waveguiding cones identified with white arrows in (E).
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Cone and cone-rod dystrophies
Cone-rod dystrophy
Using an AO flood-illuminated ophthalmoscope,76 one subject 
has been imaged showing a lack of waveguiding cones within 
clinically apparent atrophic regions and a contiguous cone 
mosaic elsewhere with enlarged cones and reduced peak cone 
densities. A correlation was observed between cone densities and 
multifocal ERG (mfERG) peak amplitudes. Similar observations, 
including structure-function correlation with mfERG, have been 
observed in three further studies of nine subjects in total.69 77 78 
AOSLO cone spacing measurements also correlated significantly 
with mfERG amplitude, retinal sensitivity and VA.69 76–78
Cone dystrophy with supernormal rod responses
Vincent et al assessed macular morphology in cone dystrophy 
with supernormal rod responses with cAOSLO and reported 
decreased cone densities and a disrupted mosaic, with cones in 
groups, surrounded by patches of absent or non-waveguiding 
cones.79 It will be of interest to further investigate subjects with 
SD-AOSLO to probe whether the non-waveguiding cones are 
indeed absent or whether inner segments are present.
Chorioretinal dystrophies
Choroideremia
Patchy cone loss in symptomatic carriers and a normal photo-
receptor mosaic in asymptomatic carriers have been observed.80 
Disrupted parafoveal mosaics, with increased cone spacing, 
were seen in affected men, with more regular spacing near the 
borders of atrophy.80 In combination with OCT findings, likely 
simultaneous degeneration of the RPE and photoreceptors was 
suggested. The largest multimodal study to date including the 
use of cAOSLO81 describes a relatively intact central retina with 
a normal or reduced cone density at 0.5 mm eccentricity; and 
an abrupt loss of cones at the border of RPE atrophy, as well 
as hyper-reflective clumps of cones in younger patients (<30 
years) and bubble-like lesions within the choroid; findings also 
identified by Sun et al.22 No RPE cells were visible in areas of 
cone loss, with IZ dropout preceding EZ disruption.81 Investi-
gators thereby proposed that choroideremia (CHM) is primarily 
an RPE disorder followed by photoreceptor degeneration, with 
implications for intervention and the ongoing debate on cellular 
pathogenesis of CHM.
Only by using non-confocal SD-AOSLO22 has reliable visual-
isation of cones been possible in the bordering areas of atrophy, 
with abnormal and heterogeneous morphology, density and 
diameter. The cone mosaic terminates sharply before those 
areas, in direct contrast to previously reported RP transition 
zone imaging, which may relate to the likely primary RPE 
pathology in CHM. This study also concluded that RPE degen-
eration precedes photoreceptor loss.
These studies have resulted in AOSLO being incorporated 
in many ongoing CHM gene therapy trials and natural history 
studies.22 80 81
dIscussIon And future possIbIlItIes
IRDs are the most genetically and phenotypically heterogeneous 
conditions in medicine, with certain genotypes being extremely 
rare making it challenging to establish large informative cohorts, 
suggesting the need for multicentre studies. Many of the studies 
incorporated in our review highlight the need for longitudinal 
monitoring. Insights into disease progression are of great value 
including identification of the optimal therapeutic window and 
participant stratification.
AO ophthalmoscopy offers invaluable identification of struc-
tural detail on a cellular level, with several studies described 
herein exploring correlation between structure and function. 
Evolving AO-guided retinal sensitivity assessments (‘nanoper-
imerty’) will better allow correlation between cellular imaging 
and functional testing with exquisite retinotopic precision.82–84
One major common limitation is the challenge in imaging 
patients with nystagmus (eg, ACHM) and/or poor fixation (eg, 
STGD). Eye tracking systems incorporated into AO systems85–87 
can allow imaging of more subjects and improve data acquisition. 
Moreover, image processing and analysis are substantial bottle-
necks that developments in, for example, machine learning, will 
hopefully solve in the near future, thereby allowing a broader 
application of AO technology.
While our review concentrates on IRDs, AO has been applied 
to many other conditions including albinism,14 age-related 
macular degeneration,88 89 diabetic retinopathy90 and auto-
immune retinopathy,91 and also in basic and applied research, 
including facilitating insights in visual system neurophysiology.92
conclusIons
AO is a rapidly evolving field, which has a place in diagnosis, 
advice on prognosis, monitoring and management of IRDs. It can 
also probe underlying pathophysiology and facilitate improved 
understanding of cellular retinal anatomy and biology. We antic-
ipate an increasing use of AO systems in the future due to the 
complementary information they provide compared with other 
imaging modalities and the ability to target functional measure-
ments on individual cells, with particular application in longitu-
dinal natural history studies and ongoing/planned interventional 
trials both for participant selection and monitoring treatment 
safety and efficacy.
methods of lIterAture seArch
PubMed was searched for articles related to AO and IRDs up 
to June 2017 with key words: Adaptive Optics, AO, AOSLO, 
Retinal Imaging individually and in combination with the condi-
tions’ name (eg, Achromatopsia) as well as their abbreviations 
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